Experts Discuss Roundup Cancer Link at Monsanto Science Week

Monsanto Science Week marked the first time that the science behind the company’s Roundup weed killer was scrutinized under oath. Expert witnesses from both sides, including epidemiologists, toxicologists and others analyzed relevant research in open court before U.S. District Court Judge Vince Chhabria in what is formally known as a [...]

By | 2018-04-06T17:11:10+00:00 March 9th, 2018|Blog, Monsanto Roundup News, Michael L. Baum|

Expert Witnesses to Face Off in Roundup Cancer Hearing Next Week

Both Sides of Roundup Cancer Lawsuits Present Experts at Monsanto MDL Daubert Hearing on March 5 March 4, 2018 – San Francisco, California - - A Daubert Hearing for the federal Monsanto Roundup litigation is scheduled to begin on Monday, March 5, 2018 at U.S. District Court, Northern District of California [...]

Baum Hedlund Urges DOJ to Reopen Investigation re Celexa / Lexapro Clinical Trials

Boston, Massachusetts – February 8, 2018 - - The law firm of Baum, Hedlund, Aristei & Goldman has sent a letter and memorandum to the U.S. Attorney’s Office (USAO) for the District of Massachusetts calling for the reopening of its investigation and prosecution of Forest Laboratories Inc. and its subsidiary, [...]

Defending IARC’s Scientific Integrity Against Congressional Attack

Feb. 6, 2018 – Washington D.C. - - Today’s Science, Space, Technology (SST) Committee Hearing, ironically titled, “In Defense of Scientific Integrity: Examining the IARC Monograph Programme and Glyphosate Review,” should probably have been named “Monsanto’s Daily Glyphosate Talking Points.” The hearing, headed by Rep. Lamar Smith (R-TX), started with reiterating the same [...]

Germany Ignores Environment Minister Over Glyphosate License in the EU

Nov. 28, 2017 – Brussels, Belgium -- The European Commission has approved a new five-year license for glyphosate, the active ingredient in Monsanto’s Roundup weed killer. The result of yesterday’s vote allows for glyphosate-based herbicides like Roundup to be purchased and sprayed in the EU without any restrictions on use. [...]

By | 2017-11-30T12:29:20+00:00 November 28th, 2017|Blog, Monsanto Roundup News, Michael L. Baum|

Acthar Class Action Accuses Mallinckrodt of Inflating Price 85,000%

Los Angeles, California - - A class action lawsuit filed on behalf of numerous Medicare Advantage Organizations (MAOs) accuses pharmaceutical manufacturer Mallinckrodt (MNK) of engaging in a scheme to drastically inflate the price and reduce competition for its drug H.P. Acthar Gel (Acthar), a drug primarily prescribed for infants with [...]

MEPs Want to Ban Glyphosate in the EU Within Five Years

Oct. 24, 2017 – Brussels, Belgium - - Members of European Parliament (MEPs) sent a strong message today regarding the European Commission’s proposal on glyphosate, the active ingredient in Monsanto’s Roundup weed killer. MEPs announced their opposition to the European Commission’s proposal to renew the controversial herbicide’s license for a [...]

By | 2017-11-03T14:55:33+00:00 October 24th, 2017|Monsanto Roundup News, Michael L. Baum, R. Brent Wisner|

US Attorneys Urge EU to Investigate Monsanto Science Manipulation

Brussels, Belgium – Oct. 5, 2017 - - Baum, Hedlund, Aristei & Goldman attorneys R. Brent Wisner and managing partner Michael Baum have asked European Union (EU) officials to conduct an official inquiry into Monsanto’s manipulation of science and potential collusion with regulators. The request comes days before an October [...]

Roundup Cancer Victims and Attorneys in EU Ahead of Glyphosate Meeting

Two American Roundup cancer victims and their attorneys are in Europe this week to warn officials about the cancer risk associated with glyphosate. Teri McCall of Cambria, California and John Barton of Bakersfield, California were invited to Brussels to discuss the dangers of Roundup the same week that European governments [...]

By | 2017-10-25T17:57:35+00:00 October 4th, 2017|Blog, Monsanto Roundup News, Michael L. Baum, R. Brent Wisner|

Judge Refuses GlaxoSmithKline Motion for New Paxil Suicide Trial

Chicago, Illinois -- A federal judge has entered judgment against GlaxoSmithKline (“GSK”) affirming the April 20, 2017 jury verdict in favor of Wendy Dolin who alleged her husband’s 2010 suicide was the result of side effects he suffered while taking generic Paxil (paroxetine). Following the jury’s $3,000,000 verdict in Dolin’s [...]

By | 2017-09-15T16:16:20+00:00 September 14th, 2017|Blog, Paxil News, Pharma News, Press Releases, Michael L. Baum, R. Brent Wisner|